GE Healthcare Introduces Biacore T100 Immunogenicity Package

GE Healthcare announced that it is has introduced a new immunogenicity software package for its Biacore™ T100 label-free protein interaction analysis system, to support screening, confirmation and characterization of anti-drug antibodies during preclinical and clinical development.

Biacore T100 Immunogenicity Package addresses the problem of drug interference by enabling measurement of anti-drug antibodies in the presence of excess amounts of drug. The new package also includes guidelines and recommendations for development of immunogenicity assays, leading to reduced assay development time.

Screening of anti-drug antibodies with Biacore instruments has the advantage of detecting early immune responses, which are characterized by antibodies with low affinity and that interact with the drug with rapid kinetics. Such immune responses are important in efficacy and safety studies, and may be missed by alternative technologies such as end-point assays.

Tools provided by Biacore T100 Immunogenicity Package also allow for confirmation of positive samples and elimination of false positives through drug depletion. Comprehensive characterization of immune response by e.g. determination of antibody isotype and anti-drug antibody binding stability can be achieved using dedicated software tools included in Biacore T100 Immunogenicity Package.

Biacore T100 is used throughout the drug discovery and development process, from early research to QC, in labs ranging from major pharmaceutical companies to academic research institutes.

QIAGEN N.V. and Natera, Inc., a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System.